BC Extra | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
BC Extra | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
BC Extra | Jan 15, 2019
Company News

Management tracks: Immunocore gains second ex-AZ exec

Immunocore Ltd. (Abingdon, U.K.) said it hired David Berman in September as head of R&D. Berman was SVP and head of immuno-oncology at AstraZeneca plc (LSE:AZN; NYSE:AZN), and before that was head of early stage...
BC Extra | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
BC Extra | Jul 30, 2018
Company News

Management Tracks: Abeona, BioDelivery

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) hired Max Colao as chief commercial officer. He was SVP of U.S. commercial operations at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) hired Kevin...
BC Extra | Jun 5, 2018
Company News

Management tracks: Sarepta, Gilead

Neuromuscular disease company Sarepta Therapeutics Inc. (NASDAQ:SRPT) hired Louise Rodino-Klapac as VP of gene therapy at its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc. (New...
BC Week In Review | May 25, 2018
Financial News

BioDelivery Sciences raises $50M in registered direct offering

Neurology company BioDelivery Sciences International Inc. (NASDAQ:BDSI) raised $50 million in a registered direct offering through the sale of 5,000 shares of series B non-voting convertible preferred stock at $10,000 per share. The offering was...
BC Extra | May 7, 2018
Company News

Management tracks: Adverum, Evolus

Adverum Biotechnologies Inc. (NASDAQ:ADVM) said President and CEO Amber Salzman has stepped down. CFO and SVP Leone Patterson is acting as interim president and CEO while the gene therapy company searches for a successor. Additionally,...
BC Extra | Sep 1, 2017
Company News

Management tracks: BioDelivery, Almirall, Nabriva

Neurology company BioDelivery Sciences International Inc. (NASDAQ:BDSI) said President and CEO Mark Sirgo will retire at the end of the year. Sirgo will remain vice chairman of the board. The company is seeking a replacement....
BC Innovations | Feb 16, 2017
Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
Items per page:
1 - 10 of 229
BC Extra | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
BC Extra | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
BC Extra | Jan 15, 2019
Company News

Management tracks: Immunocore gains second ex-AZ exec

Immunocore Ltd. (Abingdon, U.K.) said it hired David Berman in September as head of R&D. Berman was SVP and head of immuno-oncology at AstraZeneca plc (LSE:AZN; NYSE:AZN), and before that was head of early stage...
BC Extra | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
BC Extra | Jul 30, 2018
Company News

Management Tracks: Abeona, BioDelivery

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) hired Max Colao as chief commercial officer. He was SVP of U.S. commercial operations at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) hired Kevin...
BC Extra | Jun 5, 2018
Company News

Management tracks: Sarepta, Gilead

Neuromuscular disease company Sarepta Therapeutics Inc. (NASDAQ:SRPT) hired Louise Rodino-Klapac as VP of gene therapy at its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc. (New...
BC Week In Review | May 25, 2018
Financial News

BioDelivery Sciences raises $50M in registered direct offering

Neurology company BioDelivery Sciences International Inc. (NASDAQ:BDSI) raised $50 million in a registered direct offering through the sale of 5,000 shares of series B non-voting convertible preferred stock at $10,000 per share. The offering was...
BC Extra | May 7, 2018
Company News

Management tracks: Adverum, Evolus

Adverum Biotechnologies Inc. (NASDAQ:ADVM) said President and CEO Amber Salzman has stepped down. CFO and SVP Leone Patterson is acting as interim president and CEO while the gene therapy company searches for a successor. Additionally,...
BC Extra | Sep 1, 2017
Company News

Management tracks: BioDelivery, Almirall, Nabriva

Neurology company BioDelivery Sciences International Inc. (NASDAQ:BDSI) said President and CEO Mark Sirgo will retire at the end of the year. Sirgo will remain vice chairman of the board. The company is seeking a replacement....
BC Innovations | Feb 16, 2017
Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
Items per page:
1 - 10 of 229